The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

被引：0
|
作者：
Szpechcinski, A. [1 ]
Bryl, M. [2 ]
Wojda, E. [1 ]
Czyzewicz, G. [3 ]
Swiniuch, D. [4 ]
Szwiec, M. [5 ]
Ramlau, R. [4 ]
Sliwinski, P. [1 ]
Barinow-Wojewodzki, A. [2 ]
Chorostowska-Wynimko, J. [1 ]
机构：
[1] Inst TB & Lung Dis, Warsaw, Poland
[2] EJ Zeyland Wielkopolska Ctr Pulmonol & Thorac Sur, Poznan, Poland
[3] John Paul II Specialist Hosp, Krakow, Poland
[4] Med Univ Poznan, Poznan, Poland
[5] Univ Hosp Zielona Gora, Zielona Gora, Poland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; EGFR mutations; liquid biopsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [21] Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1236 - S1236
  • [22] Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
    Chen, S.
    Zhao, J.
    Cui, L.
    Liu, Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (03) : 332 - 340
  • [23] The Prognostic Value of Metastasis to Different Organs in EGFR-Mutated Stage IV NSCLC Patients Treated with First-Line Icotinib
    Wang, Y.
    Wang, L.
    Zuo, J.
    Feng, L.
    Fan, Z.
    Zhang, X.
    Han, J.
    Zhou, X.
    Li, B.
    Su, N.
    Du, H.
    Zhou, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S420 - S421
  • [24] A Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC with EGFR Mutations
    Yong, H.
    Hui, L.
    Fang, L.
    Dong, L.
    Ling, X.
    Qiang, W.
    Peng, X.
    Hua, H.
    Yang, Y.
    Ping, G.
    Cui, K.
    Wu, W.
    Yu, C.
    Huo, L.
    Qiang, X.
    Xi, S.
    Jin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S593
  • [25] Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
    Furugaki, Koh
    Iwai, Toshiki
    Moriya, Yoichiro
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    LUNG CANCER, 2014, 83 (01) : 44 - 50
  • [26] Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China
    Guan, Haijing
    Wang, Chunping
    Chen, Chen
    Han, Sheng
    Zhao, Zhigang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [28] Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors
    Jiang, Tao
    Zhao, Jing
    Zhao, Chao
    Li, Xuefei
    Shen, Jiqiao
    Zhou, Juan
    Ren, Shengxiang
    Su, Chunxia
    Zhou, Caicun
    O'Brien, Mary
    CLINICAL LUNG CANCER, 2019, 20 (02) : 124 - +
  • [29] Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
    Wu, Xuan
    Liang, Wenhua
    Hou, Xue
    Lin, Zhong
    Zhao, Hongyun
    Huang, Yan
    Fang, Wenfeng
    Zhao, Yuanyuan
    Wu, Jingxun
    Yang, Yunpeng
    Xue, Chong
    Hu, Zhihuang
    Zhang, Jing
    Zhang, Jianwei
    Ma, Yuxiang
    Zhou, Ting
    Qin, Tao
    Zhang, Li
    ONCOTARGETS AND THERAPY, 2013, 6 : 1481 - 1491
  • [30] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
    Holleman, Marscha S.
    Al, Maiwenn J.
    Zaim, Remziye
    Groen, Harry J. M.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01) : 153 - 164
12345